Ask AI
ProCE Banner Activity

Optimizing CKM Syndrome Care: Strategies for Employing Evidence-Based, Guideline-Recommended Therapies

Clinical Thought

Learn how cardiovascular–kidney–metabolic (CKM) conditions are interconnected and take home expert-informed strategies for treating CKM syndrome via novel, evidence-based treatments, including SGLT2 inhibitors, RAS inhibitors, and incretin-based therapies.

Released: February 16, 2026

Continue Activity View Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education.

ProCE Banner

Supporters

Supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company.

Boehringer Ingelheim Pharmaceuticals, Inc.

Eli Lilly and Company

Target Audience

This educational activity is intended for cardiology physicians, nurse practitioners, and physician associates who care for patients with HF and/or CKD (with or without diabetes).

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify persistent gaps in the care of patients with cardio-renal-metabolic disease and the clinical impact of delayed intervention

  • Evaluate emerging evidence on the broad benefits of SGLT2 inhibitors in CRM care to inform earlier initiation and sustained use in appropriate patients

  • Formulate strategies for effective patient counseling around integration of SGLT2 inhibitors into personalized care plans for patients with CRM conditions

Disclosure

Primary Author

Michelle Kittleson, MD, PhD, has no relevant financial relationships to disclose.